Navigation Links
CareFusion Reports First Quarter Fiscal 2012 Results
Date:11/7/2011

with the FDA and our failure to comply with the requirements of the amended consent decree may have an adverse effect on our business; and our success depends on our key personnel, and the loss of key personnel or the transition of key personnel, including our chief executive officer, could disrupt our business. The CareFusion news release and the information contained herein reflect management's views as of Nov. 7, 2011. Except to the limited extent required by applicable law, CareFusion undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.CAREFUSION CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF INCOME(UNAUDITED)Quarter Ended September 30,(in millions, except per share amounts)20112010Revenue

$

844

$

811Cost of Products Sold417398Gross Margin427413Selling, General and Administrative Expenses273272Research and Development Expenses3940Restructuring and Acquisition Integration Charges722Operating Income10879Interest Expense and Other, Net 2523Income Before Income Tax8356Provision for Income Tax1620Income from Continuing Operations6736Income from Discontinued Operations, Net of Tax-2Net Income

$

67

$

38Per Share Amounts:(1)Basic Earnings per Common Share:Continuing Operations

$

0.30

$

0.17Discontinued Operations

$

-

$

0.01Basic Earnings per Common Share

$

0.30

$

0.17Diluted Earnings per Common Share:Continuing Operations

$

0.30

$

0.17Discontinued Operations

$

-

$

0.01Diluted Earnings per Common Share

$

0.30

$

0.17Weighted-Average Number of Common Shares Outstanding:Basic223.8222.1Diluted226.3223.9____________1Earnings per share calculations are performed separately for each component presented.  Therefore, the sum of the per share components from th
'/>"/>

SOURCE CareFusion
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ERT Closes the Acquisition of the Research Services Division of CareFusion Corporation
2. Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011
3. InterMune Reports Third Quarter 2011 Financial Results and Business Highlights
4. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
5. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
6. Caliper Life Sciences Reports Third Quarter 2011 Results
7. Neurocrine Biosciences Reports Third Quarter 2011 Results
8. United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
9. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
10. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
11. ReportsnReports: Depression Therapeutics Market to Reach $10.9 Billion by 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... 2015 - Development of a ... the VOLVOX Platform - To be Presented on Tuesday, ...  Supramolecular Assembly of Antibody-drug Conjugates Using an anti-HER2 Monoclonal ... Sunday, Apr 19, 1:00 PM EST Invictus ... today announced that the company,s novel computational platform technology ...
(Date:4/20/2015)... MIAMI (PRWEB) April 20, 2015 ... attend The Aesthetic Meeting 2015, an annual gathering of ... Alfredo Hoyos, M.D., is scheduled to introduce the company’s ... injection techniques with adipose-derived stem cell techniques. , ... that concern patients in the aesthetic field, including facial ...
(Date:4/17/2015)... PA (PRWEB) April 17, 2015 ... a leader in regulatory data management, preparation, and submission ... today the availability of a new Lot Distribution Report ... are required to remain compliant with the FDA’s new ... by the FDA to monitor the volume and timing ...
(Date:4/17/2015)... SYDNEY , April 17, 2015  US-Australian drug ... signed a Memorandum of Understanding with the Feinstein ... New York to collaborate with ... cancers. The collaboration brings together the ... and clinical expertise of the Feinstein Institute in ...
Breaking Biology Technology:Invictus Oncology Announces Two Posters to be Presented Describing its Platform Technology on Supramolecular Therapeutics at the American Association for Cancer Research Annual Meeting, 2015 2Global Stem Cells Group to Host Featured Speaker at The Aesthetic Meeting 2015 in Montreal 2Global Stem Cells Group to Host Featured Speaker at The Aesthetic Meeting 2015 in Montreal 3Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 2Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 4Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 5Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 6
... - Conference Call to Discuss Results to Be Held at ... Incorporated,s (Nasdaq: VPHM ) first quarter financial results ... 29, 2009 before the open of the U.S. financial markets.The ... at 9:00 a.m. Eastern Time on the same day. ...
... Human Tissue Collection and Specimen Management Provide FocusMEMPHIS, ... the physician partners of Accelerated Community Oncology Research ... (USA), has begun acquiring human tissue samples for ... World BioBank supports biomarker storage in conjunction with ...
... Calif., April 22 Metabolex, Inc., a biopharmaceutical company ... therapeutics for the treatment of diabetes and related metabolic ... to its Board of Directors. Mr. von Emster currently ... November 2000 to March 2009, Mr. von Emster was ...
Cached Biology Technology:ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009 2World BioBank(TM) Launch Benefits Advanced Medical Research 2World BioBank(TM) Launch Benefits Advanced Medical Research 3Metabolex Announces Election of Kurt von Emster to Board of Directors 2
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... revenues for Q1 2015 attributed to somewhat higher than ... company in the year-end report 2014 that revenues for ... MSEK that the company reported for Q4 2014. The ... continue to be negative. The complete interim report will ...
(Date:4/1/2015)... Medisafe ™, the leading global medication management platform with ... Android smartphones and tablets, announces today that ... allow patients to track and correlate their adherence directly ... be able to visualize in real-time how taking medication ... glucose levels and blood pressure. "Patients need ...
(Date:3/30/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has ... Market in Automotive Sector 2014-2018" report to their ... Recognition market in Automotive Sector to grow at a ... Gesture recognition is the ability of a device to ... Gesture recognition technology can be 2D-based or 3D-based. It ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... that freezing kidney tumors through percutaneous cryoablation shows promise ... Their early findings showing short-term success in more ... this month’s issue of Radiology. , The standard treatment ... of a long-term cure. For some patients, surgery ...
... Medicine has helped confirm the reliability of a new ... long-promised era of personalized medicine based on each individual's ... five sites that helped determine that the genetic test ... developing cirrhosis from chronic hepatitis C infection. That means ...
... A study of eight hospitals in Peru has shown ... double that of mechanically ventilated negative-pressure rooms and 18 ... , The researchers, led by Rod Escombe from ... ventilated clinical rooms such as respiratory isolation rooms, TB ...
Cached Biology News:Cryoablation -- A new treatment option for some kidney tumor patients 2Cryoablation -- A new treatment option for some kidney tumor patients 3New test helps identify hepatitis C patients at high risk of developing cirrhosis 2New test helps identify hepatitis C patients at high risk of developing cirrhosis 3
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
Mouse monoclonal [RIZ1723] to PRDM2/RIZ...
MagSi uniform silica particles coated with a carboxyl group containing polymer, covalently attached to the bead surface....
Mouse monoclonal [1241] to Parainfluenza Virus type 2...
Biology Products: